<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">J Med Virol</span><span class="iso-abbrev" title="iso-abbrev">J. Med. Virol</span><span class="doi" title="doi">10.1002/(ISSN)1096-9071</span><span class="publisher-id" title="publisher-id">JMV</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Journal of Medical Virology</span></div><span class="issn-ppub" tagx="issn" title="issn-ppub">0146-6615</span><span class="issn-epub" tagx="issn" title="issn-epub">1096-9071</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">John Wiley and Sons Inc.</span><span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">Hoboken</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7267113">7267113</a></span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1002/jmv.25961">10.1002/jmv.25961</a></span><span class="publisher-id" title="publisher-id">JMV25961</span><div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Review</span>: <span class="subject" title="subject">Reviews</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
Convalescent plasma transfusion for the treatment of COVIDâ€�19: Systematic review</div> <div class="alt-title" title="alt-title">
RAJENDRAN <div class="sc_UNKNOWN">
et al.</div> </div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rajendran</span><span class="given-names" tagx="given-names" title="given-names">Karthick</span></span><span class="degrees" tagx="degrees" title="degrees">PhD</span><span class="contrib-id" tagx="contrib-id" title="contrib-id">http://orcid.org/0000-0003-3938-3347</span><span class="role" tagx="role" title="role">Research Scientist II</span><a href="#jmv25961-aff-0001"><sup>1</sup></a><span class="address" title="address"><span class="email" tagx="email" title="email">rkarthickphd@gmail.com</span></span></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Krishnasamy</span><span class="given-names" tagx="given-names" title="given-names">Narayanasamy</span></span><span class="degrees" tagx="degrees" title="degrees">DM</span><span class="role" tagx="role" title="role">Prof &amp;amp; Dir</span><a href="#jmv25961-aff-0002"><sup>2</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rangarajan</span><span class="given-names" tagx="given-names" title="given-names">Jayanthi</span></span><span class="degrees" tagx="degrees" title="degrees">MD, FRCP(Glasgow)</span><span class="role" tagx="role" title="role">Prof of Medicine, Dean</span><a href="#jmv25961-aff-0003"><sup>3</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rathinam</span><span class="given-names" tagx="given-names" title="given-names">Jeyalalitha</span></span><span class="degrees" tagx="degrees" title="degrees">MD</span><span class="role" tagx="role" title="role">Prof of Pharmacology</span><a href="#jmv25961-aff-0003"><sup>3</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Natarajan</span><span class="given-names" tagx="given-names" title="given-names">Murugan</span></span><span class="degrees" tagx="degrees" title="degrees">MD</span><span class="role" tagx="role" title="role">Associate Prof of Pulmonary Medicine</span><a href="#jmv25961-aff-0003"><sup>3</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ramachandran</span><span class="given-names" tagx="given-names" title="given-names">Arunkumar</span></span><span class="degrees" tagx="degrees" title="degrees">PhD</span><span class="role" tagx="role" title="role">Research Scientist I</span><a href="#jmv25961-aff-0001"><sup>1</sup></a></span></div><span class="citation_author_institution" id="jmv25961-aff-0001">[1], <span class="named-content" title="named-content">Multidisciplinary Research Unit (MRU)</span><span class="institution" title="institution">Madras Medical College</span><span class="city" tagx="city" title="city">Chennai</span><span class="named-content" title="named-content">Tamil Nadu</span><span class="country" tagx="country" title="country">India</span></span><span class="citation_author_institution" id="jmv25961-aff-0002">[2], <span class="named-content" title="named-content">Madras Medical College</span><span class="institution" title="institution">Institute of Hepatobiliary Sciences</span><span class="city" tagx="city" title="city">Chennai</span><span class="named-content" title="named-content">Tamil Nadu</span><span class="country" tagx="country" title="country">India</span></span><span class="citation_author_institution" id="jmv25961-aff-0003">[3], <span class="named-content" title="named-content">Institute of Internal Medicine</span><span class="institution" title="institution">Madras Medical College</span><span class="city" tagx="city" title="city">Chennai</span><span class="named-content" title="named-content">Tamil Nadu</span><span class="country" tagx="country" title="country">India</span></span><div class="author-notes" title="author-notes"> <div class="corresp" title="corresp"><span class="label" tagx="label" title="label">*</span><b>Correspondence</b><br /><br /> Karthick Rajendran,Â PhD, Research Scientist II, Multidisciplinary Research Unit (MRU), Madras Medical College,Â Tamil Nadu, Chennai 600003, India.<br /><br /> Email: <span class="email" tagx="email" title="email">rkarthickphd@gmail.com</span><br /><br /></div> </div><span class="pub-date-epub" title="pub-date-epub">epub: <span>2020-5-5</span></span><span class="elocation-id" tagx="elocation-id" title="elocation-id">10.1002/jmv.25961</span><span class="history" title="history"><span class="received" title="received">received: 2020-4-20</span><span class="accepted" title="accepted">accepted: 2020-4-29</span></span><div class="permissions"><span class="copyright" title="copyright">(C) , </span><span class="license" title="license"><span class="license-p" title="license-p">This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</span></span></div><a class="self-uri" href="file:JMV-9999-na.pdf" title="self-uri">file:JMV-9999-na.pdf</a><div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <div class="title" tagx="title" title="title">
Abstract</div> <p>The recent emergence of coronavirus disease 2019 (COVIDâ€�19) pandemic has reassessed the usefulness of historic convalescent plasma transfusion (CPT). This review was conducted to evaluate the effectiveness of CPT therapy in COVIDâ€�19 patients based on the publications reported till date. To our knowledge, this is the first systematic review on convalescent plasma on clinically relevant outcomes in individuals with COVIDâ€�19. PubMed, EMBASE, and Medline databases were searched upto 19 April 2020. All records were screened as per the protocol eligibility criteria. We included five studies reporting CPT to COVIDâ€�19 patients. The main findings from available data are as follows: (a) Convalescent plasma may reduce mortality in critically ill patients, (b) Increase in neutralizing antibody titers and disappearance of SARSâ€�CoVâ€�2 RNA was observed in almost all the patients after CPT therapy, and (c) Beneficial effect on clinical symptoms after administration of convalescent plasma. Based on the limited scientific data, CPT therapy in COVIDâ€�19 patients appears safe, clinically effective, and reduces mortality. Wellâ€�designed large multicenter clinical trial studies should be conducted urgently to establish the efficacy of CPT to COVIDâ€�19 patients.</p> </div> <div class="kwd-group"> <div class="kwd" title="kwd">
convalescent plasma transfusion (CPT)</div> <div class="kwd" title="kwd">
COVIDâ€�19</div> <div class="kwd" title="kwd">
neutralizing antibody</div> <div class="kwd" title="kwd">
SARSâ€�CoVâ€�2</div> </div> <div class="counts" title="counts"><span class="fig-count" title="fig-count">fig-count: </span><span class="table-count" title="table-count">table-count: </span><span class="page-count" title="page-count">page-count: </span><span class="word-count" title="word-count">word-count: </span></div> <div class="custom-meta-group" title="custom-meta-group"> <meta name="source-schema-version-number" value="2.0" /> <meta name="edited-state" value="corrected-proof" /> <meta name="details-of-publishers-convertor" value="Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.3 mode:remove_FC converted:03.06.2020" /> </div> </div> <p content-type="self-citation"><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Rajendran</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Krishnasamy</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Rangarajan</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Rathinam</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Natarajan</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ramachandran</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>. <span class="mixed-article-title" title="mixed-article-title">Convalescent plasma transfusion for the treatment of COVIDâ€�19: Systematic review</span>. <span class="source" tagx="source" title="source">J Med Virol</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="fpage" tagx="fpage" title="fpage">1</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>. <span class="pub-id"><a href="https://dx.doi.org/10.1002/jmv.25961">10.1002/jmv.25961</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31502247">31502247</a></span></span></p> </div> <div class="body" title="body"> <div class="introduction" title="sec"><span class="label" tagx="label" title="label">1</span><div class="title" tagx="title" title="title">
INTRODUCTION</div> <p>The recent coronavirus disease 2019 (COVIDâ€�19) epidemic developed into an unprecedented global public health crisis with significant humanitarian consequences. As of 19 April 2020, the World Health Organization has been informed of 2â€‰241â€‰359 confirmed cases of COVIDâ€�19, with 152â€‰551 deaths (6.8%) documented worldwide.<a href="#jmv25961-bib-0001"><sup>1</sup></a></p> <p>The current treatment of COVIDâ€�19 caused by novel coronavirus SARSâ€�CoVâ€�2 has been limited to general supportive care, with provision of critical care as no approved therapies or vaccines are available.<a href="#jmv25961-bib-0002"><sup>2</sup></a></p> <p>The clinical data for the studies involving COVIDâ€�19 are still scarce and limited to data from China, Spain, Italy, United States of America, Germany, France, The United Kingdom, and other international registries. This will be a problem when predicting treatment outcomes.</p> <p>Passive immunization therapy has been successfully used to treat infectious diseases back to the 1890s. An individual who is sick with infectious diseases and recovers has blood drawn and screened for particular microorganism neutralizing antibodies. Following identification of those with high titers of neutralizing antibody, convalescent plasma containing these neutralizing antibodies can be administered in individuals with specified clinical disease to reduce symptoms and mortality. Hence, convalescent plasma transfusion (CPT) has been the subject of increasing attention, especially in the wake of largeâ€�scale epidemics.<a href="#jmv25961-bib-0003"><sup>3</sup></a> It has recently been suggested by Food and Drug Administration that administration and study of investigational CPT may provide a clinical effect for treatment of COVIDâ€�19 during the public health emergency.<a href="#jmv25961-bib-0004"><sup>4</sup></a></p> <p>We conducted a systematic review to evaluate available data for the clinical effectiveness of convalescent plasma for the treatment of COVIDâ€�19. This will help to provide clinicians and scientists with an overview of scientific evidence on a potential treatment option and better clinical management of critically ill COVIDâ€�19 patients.</p> </div> <div class="methods" title="methods"><span class="label" tagx="label" title="label">2</span><div class="title" tagx="title" title="title">
METHODS</div> <div class="protocolandregistration" title="sec"><span class="label" tagx="label" title="label">2.1</span><div class="title" tagx="title" title="title">
Protocol and registration</div> <p>This systematic search was carried out in major electronic databases (PubMed, Embase, and Medline) to identify available evidence providing Information on the CPT for treatment of COVIDâ€�19 in accordance with the preferred reporting items for systematic reviews and metaâ€�analyses guidelines.<a href="#jmv25961-bib-0005"><sup>5</sup></a> Due to the urgency of the matter and anticipated long waiting period, we were not able to wait for registration of this systematic review protocol (PROSPERO Submission id number: 179739).</p> </div> <div class="eligibilitycriteria" title="sec"><span class="label" tagx="label" title="label">2.2</span><div class="title" tagx="title" title="title">
Eligibility criteria</div> <div class="studydesigns" title="sec"><span class="label" tagx="label" title="label">2.2.1</span><div class="title" tagx="title" title="title">
Study designs</div> <p>Study designs from the selected publication reported CPT in COVIDâ€�19 patients included clinical trials such as randomized controlled trials, controlled clinical trials, prospective and retrospective comparative cohort studies, caseâ€�control studies; crossâ€�sectional studies, case series, and case reports.</p> </div> </div> <div class="intervention" title="sec"><span class="label" tagx="label" title="label">2.3</span><div class="title" tagx="title" title="title">
Intervention</div> <p>We included clinical studies involving assessment of CPT treatment for the COVIDâ€�19 patients.</p> <p>Study population, timing, and setting:</p> <p>Published literatures were identified between 1 December 2019 and 19 April 2020 using â€œconvalescent plasma and COVIDâ€�19â€� as search term without restrictions on the study type of setting.</p> </div> <div class="comparators" title="sec"><span class="label" tagx="label" title="label">2.4</span><div class="title" tagx="title" title="title">
Comparators</div> <p>There were no restrictions on the type of comparator in the studies.</p> </div> <div class="outcomes" title="sec"><span class="label" tagx="label" title="label">2.5</span><div class="title" tagx="title" title="title">
Outcomes</div> <p>The outcome of interest was clinical effects, survival benefits, viral load &amp;amp; antibody titer status and adverse events.</p> </div> <div class="languages" title="sec"><span class="label" tagx="label" title="label">2.6</span><div class="title" tagx="title" title="title">
Languages</div> <p>We included articles without considering any restriction of language to identify potential published studies.</p> </div> <div class="publicationstatus" title="sec"><span class="label" tagx="label" title="label">2.7</span><div class="title" tagx="title" title="title">
Publication status</div> <p>We included articles published in scientific journals.</p> </div> <div class="informationsources" title="sec"><span class="label" tagx="label" title="label">2.8</span><div class="title" tagx="title" title="title">
Information sources</div> <p>This systematic search was carried out in major electronic databases (PubMed, Embase, and Medline) to identify available evidence providing information on the CPT for treatment of COVIDâ€�19. In addition, we also searched the reference lists of selected studies.</p> </div> <div class="searchstrategy" title="sec"><span class="label" tagx="label" title="label">2.9</span><div class="title" tagx="title" title="title">
Search strategy</div> <p>The results of our database searches and records identified from other sources were documented. Removal of duplicates were also done manually and depicted in a PRISMA flow diagram.</p> </div> <div class="studyselection" title="sec"><span class="label" tagx="label" title="label">2.10</span><div class="title" tagx="title" title="title">
Study selection</div> <p>A study screen was done minimum of two authors from the search results spreadsheet, authors independently screened the titles and abstracts of studies using the inclusion criteria. Studies selected at title and abstract levels were further screened with the full text of the article for eligibility to include in our review. The studies exploring preclinical trials such as in vitro trials and studies on animal models and in silico drug screens were excluded.</p> </div> <div class="dataextractionanddataitems" title="sec"><span class="label" tagx="label" title="label">2.11</span><div class="title" tagx="title" title="title">
Data extraction and data items</div> <p>A preâ€�conceived data extraction sheet was used to extract data from selected eligible studies. Any consensus in case of disagreement was resolved by opinion of a third reviewer. The extracted information included mortality, viral load, viral antibody titers, clinical benefits, and adverse events. Outcomes were extracted in all data forms (eg, dichotomous and continuous) as reported in the included studies. The results of our databases search were documented and described in a PRISMA flow diagram (FigureÂ <a href="#jmv25961-fig-0001">1</a>).</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 1</span></a></div>   <p>PRISMA Flow chart of study selection. CPT, convalescent plasma transfusion</p>   </div> </div> <div class="riskofbiasinindividualstudies" title="sec"><span class="label" tagx="label" title="label">2.12</span><div class="title" tagx="title" title="title">
Risk of bias in individual studies</div> <p>To reduce risk of bias two authors independently assessed the included studies. Overall risk of bias was judged as low risk, unclear risk, and high risk.</p> </div> </div> <div class="results" title="results"><span class="label" tagx="label" title="label">3</span><div class="title" tagx="title" title="title">
RESULTS</div> <p>The search identified 110 sources. Following screening of titles and abstracts and removing duplicates, we evaluated eight articles in full text. Among these, we found five relevant articles (one pilot study, one preliminary communication, one novel report, one case report, one descriptive study).<a href="#jmv25961-bib-0006"><sup>6</sup></a>, <a href="#jmv25961-bib-0007"><sup>7</sup></a>, <a href="#jmv25961-bib-0008"><sup>8</sup></a>, <a href="#jmv25961-bib-0009"><sup>9</sup></a>, <a href="#jmv25961-bib-0010"><sup>10</sup></a> Extracted details for five studies are presented in TableÂ <a href="#jmv25961-tbl-0001">1</a>, including the country of study, number of patients, dosage of CPT, mortality, length of hospital stay during transfusion, critical care interventions, clinical outcome, viral load, and adverse events. The five studies include a total of 27 patients who received CPT therapies for COVIDâ€�19.</p> <div class="table-wrap_UNKNOWN" id="jmv25961-tbl-0001" content-type="Table" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 1</span> <p>The efficacy and safety of convalescent plasma transfusion (CPT) in patients with COVIDâ€�19</p>  <table frame="hsides" rules="groups"> <colgroup><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1" /></colgroup> <thead valign="bottom"> <tr style="border-bottom:solid 1px #000000" valign="bottom"> <th valign="bottom" rowspan="1" colspan="1">Author</th> <th valign="bottom" rowspan="1" colspan="1">Country</th> <th valign="bottom" rowspan="1" colspan="1">Study period</th> <th valign="bottom" rowspan="1" colspan="1">Study population</th> <th valign="bottom" rowspan="1" colspan="1">CPT dosage</th> <th valign="bottom" rowspan="1" colspan="1">Antiviral (antimicrobial drugs)</th> <th valign="bottom" rowspan="1" colspan="1">Administrated day</th> <th valign="bottom" rowspan="1" colspan="1">Status during CPT</th> <th valign="bottom" rowspan="1" colspan="1">Outcome</th> <th valign="bottom" rowspan="1" colspan="1">Viral load</th> <th valign="bottom" rowspan="1" colspan="1">Severe adverse events &amp;amp; treatment complications</th> </tr> </thead> <tbody valign="top"> <tr> <td valign="top" rowspan="1" colspan="1">Duan et al<a href="#jmv25961-bib-0006"><sup>6</sup></a></td> <td valign="top" rowspan="1" colspan="1">China</td> <td valign="top" rowspan="1" colspan="1">23 January 2020 to 19 February 2020</td> <td valign="top" rowspan="1" colspan="1">10, 6â€‰M:4â€‰F, Age (xÌƒâ€�52.5â€‰y), Cardiovascular and/or cerebrovascular diseases and HTN (nâ€‰=â€‰4)</td> <td valign="top" rowspan="1" colspan="1">200â€‰mL within 4â€‰h, antibody titer &amp;gt;1:640</td> <td valign="top" rowspan="1" colspan="1"> <p>arbidol or/and remdesivir/ribavirin/peramivir (nâ€‰=â€‰9)</p> <p>ribavirin (nâ€‰=â€‰1)</p> <p>Antibacterial/antifungal for coninfecion (nâ€‰=â€‰8)</p> </td> <td valign="top" rowspan="1" colspan="1">Onset to CPT (xÌƒ â€�16.5 d)</td> <td valign="top" rowspan="1" colspan="1">All at ICU, Mechanical ventilation (nâ€‰=â€‰3), HFNO (nâ€‰=â€‰3), Conventional LFNO (nâ€‰=â€‰2)</td> <td valign="top" rowspan="1" colspan="1"> <p>Clinical symptoms, paraclinical improved,</p> <p>Increase of oxyhemoglobin saturation within 3 d</p> <p>CP well tolerated, increase/maintain the neutralizing antibodies,</p> <p>Varying degrees of absorption of lung lesions within 7 d</p> </td> <td valign="top" rowspan="1" colspan="1">Viral load undetectable (nâ€‰=â€‰7), Neutralizing antibody increased rapidly up to 1:640 (nâ€‰=â€‰5), maintained at a high level (1:640) (nâ€‰=â€‰4)</td> <td valign="top" rowspan="1" colspan="1">No severe adverse effects, Evanescent facial red spot (nâ€‰=â€‰1)</td> </tr> <tr> <td valign="top" rowspan="1" colspan="1">Chenguang Shen et al<a href="#jmv25961-bib-0007"><sup>7</sup></a></td> <td valign="top" rowspan="1" colspan="1">China</td> <td valign="top" rowspan="1" colspan="1">20 January 2020Â to 25 March 2020</td> <td valign="top" rowspan="1" colspan="1">5, Age (range, 36â€�73â€‰y), 3M:2F, HTN; mitral insufficiency (n=1)</td> <td valign="top" rowspan="1" colspan="1">400â€‰mL of CP in 2 doses on the same day, antibody titer &amp;gt;1:1000</td> <td valign="top" rowspan="1" colspan="1">interferon alfaâ€�1b + Lopinavir/ritonavir (nâ€‰=â€‰4) + favipiravir (nâ€‰=â€‰1), arbidol + darunavir + Lopinavir/ritonavir (n=1)</td> <td valign="top" rowspan="1" colspan="1">After admission between 10 and 22 d</td> <td valign="top" rowspan="1" colspan="1">All 5 critical severe ARDS on mechanical ventilation, ECMO (nâ€‰=â€‰1)</td> <td valign="top" rowspan="1" colspan="1">Temp normalized within 3 d (nâ€‰=â€‰4), SOFA score decreased, and PAO2/FIO2 increased within 12 d (range, 172â€�276 before and 284â€�366 after), Neutralizing antibody titers increased (range, 40â€�60 before and 80â€�320 on 7th d), ARDS resolved (nâ€‰=â€‰4) at 12 d, Weaned from mechanical ventilation (nâ€‰=â€‰3) within 2 wk</td> <td valign="top" rowspan="1" colspan="1">Decreased and became negative within 12 d</td> <td valign="top" rowspan="1" colspan="1">No severe adverse effects</td> </tr> <tr> <td valign="top" rowspan="1" colspan="1">Bin Zhang et al<a href="#jmv25961-bib-0008"><sup>8</sup></a></td> <td valign="top" rowspan="1" colspan="1">China</td> <td valign="top" rowspan="1" colspan="1">16 February 2020 to 15 March 2020</td> <td valign="top" rowspan="1" colspan="1">69â€‰y/F, HTN</td> <td valign="top" rowspan="1" colspan="1">900â€‰mL in 3 doses</td> <td valign="top" rowspan="1" colspan="1">arbidol, lopinavirâ€�ritonavir, interferon alpha</td> <td valign="top" rowspan="1" colspan="1">After admission 19th d</td> <td valign="top" rowspan="1" colspan="1">Critically ill invasive mechanical ventilation</td> <td valign="top" rowspan="1" colspan="1">Extubated and nonâ€�invasion ventilation was given on 34th d, Chest CT persistent absorption of consolidation, discharged on 44th d</td> <td valign="top" rowspan="1" colspan="1">Decreased 55 Ã— 10<sup>5</sup> copies/mL (20th d) â€� 3.9 Ã— 10<sup>4</sup> copies/mL (30th d) â€� 180 copies/mL (36th d). Negative (40th, 42th d)</td> <td valign="top" rowspan="1" colspan="1">No severe adverse effects</td> </tr> <tr> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1">55â€‰y/M, COPD</td> <td valign="top" rowspan="1" colspan="1">200â€‰mL</td> <td valign="top" rowspan="1" colspan="1">arbidol, lopinavirâ€�ritonavir, interferon alphaâ€�2b</td> <td valign="top" rowspan="1" colspan="1">After admission 12th d</td> <td valign="top" rowspan="1" colspan="1">Critically ill ARDS invasive mechanical ventilation</td> <td valign="top" rowspan="1" colspan="1">pO2 increased to 97 mm Hg with OI of 198 mm Hg in 1 d, All drugs discontinued except methylprednisolone, Chest images absorption of interstitial pneumonia (13th dâ€�17th d), Discharged on (19th d)</td> <td valign="top" rowspan="1" colspan="1">Negative (18th d)</td> <td valign="top" rowspan="1" colspan="1">No adverse reactions</td> </tr> <tr> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1">73â€‰y/M, HTN &amp;amp; chronic renal fâ€�ure</td> <td valign="top" rowspan="1" colspan="1">2400â€‰mL in 8 doses</td> <td valign="top" rowspan="1" colspan="1">arbidol, lopinavirâ€�ritonavir, oseltamivir, ribavirin, interferon alphaâ€�2b</td> <td valign="top" rowspan="1" colspan="1">After admission 15th d</td> <td valign="top" rowspan="1" colspan="1">Critically ill Acute respiratory failure invasive mechanical ventilation in Vâ€�V ECMO</td> <td valign="top" rowspan="1" colspan="1">Positive antiâ€�SARSâ€�CoVâ€�2 IgG (26th d). Chest xâ€�rays absorbed infiltrative lesions but pneumothorax, Serum IgM level decreased to normal range (45th d, 46th d), Transferred to unfenced ICU for underlying diseases, multiple organ failure (50th d)</td> <td valign="top" rowspan="1" colspan="1">Negative (45th d, 46th d)</td> <td valign="top" rowspan="1" colspan="1">No adverse reactions</td> </tr> <tr> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1">31â€‰y/F, pregnant (35 wk &amp;amp; 2 d)</td> <td valign="top" rowspan="1" colspan="1">300â€‰mL</td> <td valign="top" rowspan="1" colspan="1">lopinavirâ€�ritonavir and ribavirin, Imipenem, vancomycin for coinfection</td> <td valign="top" rowspan="1" colspan="1">After admission 19th d</td> <td valign="top" rowspan="1" colspan="1">Critically ill ARDS, invasive mechanical ventilation in Vâ€�V ECMO</td> <td valign="top" rowspan="1" colspan="1">Removed CRRT, ECMO (27th d), antiâ€�SARSâ€�CoVâ€�2 IgM changed from positive to weakly positive to negative, antiâ€�SARSâ€�CoVâ€�2 IgG was persistently positive (35th d 37th d), Chest CT showed nearâ€�complete absorption of opacities, Trachea cannula removed, nasal oxygen given (40th d), Discharged (46th d)</td> <td valign="top" rowspan="1" colspan="1">Negative (40th d, 43th d)</td> <td valign="top" rowspan="1" colspan="1">No adverse reactions</td> </tr> <tr> <td valign="top" rowspan="1" colspan="1">Jin Young Ahn et al<a href="#jmv25961-bib-0009"><sup>9</sup></a></td> <td valign="top" rowspan="1" colspan="1">South Korea</td> <td valign="top" rowspan="1" colspan="1">22 February 2020 to 6 March 2020</td> <td valign="top" rowspan="1" colspan="1">71â€‰y/M</td> <td valign="top" rowspan="1" colspan="1">500â€‰mL in 2 doses at 12 h interval</td> <td valign="top" rowspan="1" colspan="1">hydroxychloroquine, lopinavir/ritonavir</td> <td valign="top" rowspan="1" colspan="1">After admission 10th d</td> <td valign="top" rowspan="1" colspan="1">Severe ARDS, mechanical ventilation</td> <td valign="top" rowspan="1" colspan="1">Weaned from the mechanical ventilator, underwent a tracheostomy</td> <td valign="top" rowspan="1" colspan="1">Ct changed 24.98 (10th d) â€� 33.96 (20th d), Negative (after 26th d)</td> <td valign="top" rowspan="1" colspan="1">No adverse reaction</td> </tr> <tr> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1">67â€‰y/F, HTN</td> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1">After admission 6th d</td> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1">Extubated and discharged on 24th d</td> <td valign="top" rowspan="1" colspan="1">Negative (after 20th d). Ct changed 20.51 (5th d) â€�36.33 (9th d)</td> <td valign="top" rowspan="1" colspan="1" /> </tr> <tr> <td valign="top" rowspan="1" colspan="1">Mingxiang Ye et al<a href="#jmv25961-bib-0010"><sup>10</sup></a></td> <td valign="top" rowspan="1" colspan="1">China</td> <td valign="top" rowspan="1" colspan="1">11 February 2020Â toÂ 18 March 2020</td> <td valign="top" rowspan="1" colspan="1">69/M</td> <td valign="top" rowspan="1" colspan="1">600â€‰mL in 3 doses</td> <td valign="top" rowspan="1" colspan="1">arbidol, levofloxacin</td> <td valign="top" rowspan="1" colspan="1">After symptom 33th d</td> <td valign="top" rowspan="1" colspan="1">Myalgia, Chest CTâ€�patchy areas of GGOs</td> <td valign="top" rowspan="1" colspan="1">Symptoms improved, GGOs resolved 37th d, Cured and ready to discharge.</td> <td valign="top" rowspan="1" colspan="1">Negative</td> <td valign="top" rowspan="1" colspan="1">No adverse reaction</td> </tr> <tr> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1">75/F</td> <td valign="top" rowspan="1" colspan="1">400â€‰mL in 2 doses</td> <td valign="top" rowspan="1" colspan="1">arbidol</td> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1">Fatigue, shortness of breath, oxygen therapy through nasal catheter, respiratory distress, Multiple consolidation</td> <td valign="top" rowspan="1" colspan="1">Symptoms improved, alleviation of respiratory distress, twoâ€�fold increase in IgM and IgG titers, consolidation gradually reduced, turned into scattered GGOs, Cured and under further clinical monitoring</td> <td valign="top" rowspan="1" colspan="1">Negative</td> <td valign="top" rowspan="1" colspan="1" /> </tr> <tr> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1">56/M, Bronchitis</td> <td valign="top" rowspan="1" colspan="1">600â€‰mL in 3 doses</td> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1">Fever, nonproductive cough, shortness of breath, Chest CTâ€�Multiple GGOs, reticular opacities, and fibrosis streak,</td> <td valign="top" rowspan="1" colspan="1">Symptoms improved, complete resolution consolidation,gradually resolution of GGOs, IgM and IgG titers increased Discharged</td> <td valign="top" rowspan="1" colspan="1">Not mentioned</td> <td valign="top" rowspan="1" colspan="1" /> </tr> <tr> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1">63/F Sjogren syndrome</td> <td valign="top" rowspan="1" colspan="1">200â€‰mL</td> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1">After symptom 40th d</td> <td valign="top" rowspan="1" colspan="1">Fever, cough, shortness of breath, decreased exercise tolerance, Chest CT â€�Multiple GGOs with consolidation and fibrosis streak</td> <td valign="top" rowspan="1" colspan="1">Symptoms improved, GGOs tended to reduce, antiâ€�SARSâ€�CoVâ€�2 IgM and IgG, Discharged 46th d</td> <td valign="top" rowspan="1" colspan="1">Negative 41th d</td> <td valign="top" rowspan="1" colspan="1" /> </tr> <tr> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1">28/F</td> <td valign="top" rowspan="1" colspan="1">200â€‰mL</td> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1">After symptom 33th d</td> <td valign="top" rowspan="1" colspan="1">Fatigue and myalgia, other symptoms</td> <td valign="top" rowspan="1" colspan="1">Discharged 39th d</td> <td valign="top" rowspan="1" colspan="1">Negative</td> <td valign="top" rowspan="1" colspan="1" /> </tr> <tr> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1">57/M</td> <td valign="top" rowspan="1" colspan="1">200â€‰mL</td> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1">After symptom 50th d</td> <td valign="top" rowspan="1" colspan="1">Fever, cough, shortness of breath and myalgia, Chest CTâ€� Extensive bilateral GGOs, respiratory distress</td> <td valign="top" rowspan="1" colspan="1">Symptoms improved, GGOs resolved, discharged 54th d</td> <td valign="top" rowspan="1" colspan="1" /> <td valign="top" rowspan="1" colspan="1" /> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""> <p>Abbreviations: ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; COVIDâ€�19, coronavirus disease 2019; CP, convalescent plasma; CT, computed tomography; Ct, computed tomography; ECMO, extracorporeal membrane oxygenation; GGOs, groundâ€�glass opacity; HFNO, Highâ€�flow nasal oxygen therapy; HFNC, highâ€�flow nasal cannula oxygenation; HTN, hypertension; ICU, Intensive care unit; IgG, immunoglobulin G; IgM, immunoglobulin M; LFNO, lowâ€�flow nasal cannula oxygenation; SARSâ€�CoVâ€�2, severe acute respiratory syndrome coronavirus 2; SOFA, sequential organ failure assessment.</p> </div> </div> <div class="permissions"><span class="copyright" title="copyright">(C) <span class="copyright-holder" tagx="copyright-holder" title="copyright-holder">John Wiley &amp;amp; Sons, Ltd.</span>, </span><span class="license" title="license"><span class="license-p" title="license-p">This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</span></span></div> </div> <p>All studies but one (South Korea) were conducted in China. In five studies, the male patients (nâ€‰=â€‰15) were larger in number than the female patients (nâ€‰=â€‰12). The age of the patients across the different studies varied from 28 to 75. Comorbidity was observed in some patients who were given CPT including COPD/Bronchitis (nâ€‰=â€‰2), Cardiovascular and cerebrovascular diseases (nâ€‰=â€‰1), hypertension (nâ€‰=â€‰7). Among hypertensive patients, one had mitral insufficiency, another one had chronic renal failure. In addition, one 63â€�yearâ€�old female patient presented with Sjogren syndrome. Another 31 years aged female COVIDâ€�19 patient was pregnant with a gestation period of 35 weeks and 2 days.</p> </div> <div class="discussion" title="discussion"><span class="label" tagx="label" title="label">4</span><div class="title" tagx="title" title="title">
DISCUSSION</div> <p>CPT has a very long history of use in the treatment of infectious disease. Its use has been well documented during the outbreak of many diseases at various periods, including spanish Influenza A (H1N1) infections in 1915 to 1917,<a href="#jmv25961-bib-0011"><sup>11</sup></a> severe acute respiratory syndrome (SARS) in 2003,<a href="#jmv25961-bib-0012"><sup>12</sup></a> pandemic 2009 influenza A (H1N1),<a href="#jmv25961-bib-0013"><sup>13</sup></a> avian influenza A (H5N1),<a href="#jmv25961-bib-0014"><sup>14</sup></a> several hemorrhagic fevers such as Ebola,<a href="#jmv25961-bib-0015"><sup>15</sup></a> and other viral infections. In addition, studies show convalescent plasma antibodies that can limit the virus reproduction in the acute phase of infection and help clear the virus, which is beneficial to the rapid recovery of the disease.<a href="#jmv25961-bib-0016"><sup>16</sup></a></p> <p>Previous reviews have stated that the CPT may be considered for critically sick COVIDâ€�19 patients based on the earlier reported studies.<a href="#jmv25961-bib-0017"><sup>17</sup></a>, <a href="#jmv25961-bib-0018"><sup>18</sup></a> In this systematic review of CPT to the COVIDâ€�19 patients, we identified and critically evaluated five studies that described about 27 patients. All studies reported good outcomes after CPT performance, but all were considered to have risk of bias owing to a combination of nonâ€�randomized evaluations, confounding, predictor description and poor methodological conduct for participant selection, dosage of CPT, and duration of therapy. This heterogeneity did not permit us to perform a metaâ€�analysis. However, the important strength of this study is a comprehensive search of published clinical study data abstraction. Our review is the first to summarize all such literature in humans with COVIDâ€�19.</p> <div class="cptdosage" title="sec"><span class="label" tagx="label" title="label">4.1</span><div class="title" tagx="title" title="title">
CPT dosage</div> <p>The doses of CPT used as described by the different studies is varied. A Chinese pilot study showed a minimal use of a single dose of 200â€‰mL convalescent plasma with neutralizing antibody titers &amp;gt;1:640. Another study by Bin Zhang et al<a href="#jmv25961-bib-0008"><sup>8</sup></a> reported a maximum of 2400â€‰mL of convalescent plasma administered to a 73 years old male patient. Due to variability of CPT doses in reports, the optimal dose of CPT for COVIDâ€�19 could not be determined. All 27 survivors received CPT between Day 6 and Day 50 after the onset of symptoms or admission to hospitals.</p> </div> <div class="antiviral,antibacterial/antifungalmedicationsadditiontocpt" title="sec"><span class="label" tagx="label" title="label">4.2</span><div class="title" tagx="title" title="title">
Antiviral, antibacterial/antifungal medications addition to CPT</div> <p>All 27 COVIDâ€�19 patients described in these five studies received more than one antiviral drug including CPT, in addition, 10 patients received antibacterial/antifungal drugs for coinfection.</p> </div> <div class="icuadmission,mechanicalventilation,lengthofstay" title="sec"><span class="label" tagx="label" title="label">4.3</span><div class="title" tagx="title" title="title">
ICU admission, mechanical ventilation, length of stay</div> <p>Most of the patients are considered critically ill who received ICU admission (nâ€‰=â€‰21) and most of the patients received mechanical ventilation during the CPT (nâ€‰=â€‰14). However, six patients received nasal cannula oxygenation in which three received HFNO and two received conventional LFNO. Acute respiratory distress syndrome (ARDS) were reported in 17 patients in which 7 received extracorporeal membrane oxygenation during CPT. The length of stay was not specified but most studies revealed data of discharge from hospital (nâ€‰=â€‰15).</p> </div> <div class="viralloadandantibodytiterlevelsaftercpt" title="sec"><span class="label" tagx="label" title="label">4.4</span><div class="title" tagx="title" title="title">
Viral load and antibody titer levels after CPT</div> <p>All five studies found that CPT significantly reduces the viral load and increase the level of neutralizing antibody over time. Viral loads also decreased and became negative between day 1 and 30 days after the CPT. Chenguang Shen et al<a href="#jmv25961-bib-0007"><sup>7</sup></a> described that IgG titers of the treated patients increased upto 145â€‰800 and the IgM titers also increased upto 145â€‰800 after CPT.</p> </div> <div class="clinicalbenefits" title="sec"><span class="label" tagx="label" title="label">4.5</span><div class="title" tagx="title" title="title">
Clinical benefits</div> <p>After receiving convalescent plasma transfusion, almost all the patients showed improvements of symptoms including their body temperature normalized, varying degrees of absorption of lung lesions, ARDS resolved, weaned from ventilation within 1 day to maximum of 35 days post transfusion.</p> </div> <div class="survival" title="sec"><span class="label" tagx="label" title="label">4.6</span><div class="title" tagx="title" title="title">
Survival</div> <p>All studies reported unanimously positive findings of zero mortality after patients received CPT in varying doses. However, it was not clearly determined that whether the high percentage of survival was due to the treatment of patients with multiple other agents (including antiviral medications) or CPT treatment or a combinatorial/synergistic effect of both. Bin Zhang et al<a href="#jmv25961-bib-0008"><sup>8</sup></a> referred that one patient (73/Male) was transferred to unfenced ICU for further treatment due to underlying diseases and multiple organ failure.</p> </div> <div class="severeadverseeventsandtreatmentcomplications" title="sec"><span class="label" tagx="label" title="label">4.7</span><div class="title" tagx="title" title="title">
Severe adverse events and treatment complications</div> <p>CPT was well tolerated by the participants in all studies. No fatality occurred in SARS CoV2â€�infected individuals administered with convalescent plasma. Duan et al<a href="#jmv25961-bib-0006"><sup>6</sup></a> mentioned a minor side effect of evanescent facial red spot in one patient administered with convalescent plasma but it was very minimal with no adverse events.</p> </div> <div class="limitations" title="sec"><span class="label" tagx="label" title="label">4.8</span><div class="title" tagx="title" title="title">
Limitations</div> <p>A lack of highâ€�quality RCT studies and relevant literature paucity limited our analyses. All the reported studies were predominately case reports or series, had no proper control groups, and had a moderate to high risk of bias.</p> </div> </div> <div class="conclusions" title="conclusions"><span class="label" tagx="label" title="label">5</span><div class="title" tagx="title" title="title">
CONCLUSION</div> <p>There is a compelling need to control the greatest global health crisis by COVIDâ€�19 outbreak. Currently, there is no reliable therapeutic options for critically ill COVIDâ€�19 contracted patients. Based on the consolidated clinical data derived from five independent studies of 27 patients suggests, in addition to antiviral/antimicrobial drugs, CPT could be an effective therapeutic option with promising evidence on safety, improvement of clinical symptoms, and reduced mortality. We recognize that a definitive conclusion cannot be drawn on optimal doses and treatment time point for the CPT to COVIDâ€�19, a large multicenter clinical trials are urgently needed to tackle this pandemic.</p> </div> <div class="COI-statement" title="COI-statement"> <div class="title" tagx="title" title="title">
CONFLICT OF INTERESTS</div> <p>The authors declare that there are no conflict of interests.</p> </div> <div class="authorcontributions" title="sec"> <div class="title" tagx="title" title="title">
AUTHOR CONTRIBUTIONS</div> <p>KR conceived the content, retrieved the data, wrote the manuscript, and approved the final version. KN retrieved the data and approved the final version. JaR, JeR retrieved the data, wrote the manuscript. MN, AR helped in data extraction, revised the manuscript critically, and approved the final version.</p> </div> </div> <div class="back" title="back"> <div class="ack" title="ack"> <div class="title" tagx="title" title="title">
ACKNOWLEDGEMENTS</div> <p>The authors would like to thank the support from the Department of Health Research (DHR), Ministry of Health &amp;amp; Family Welfare, Government of India.</p> </div> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
REFERENCES</div> <li tag="ref"><a name="jmv25961-bib-0001" /><span class="label" tagx="label" title="label">1</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="collab'">collab: World Health Organization</span> . <span class="mixed-article-title" title="mixed-article-title">Coronavirus disease 2019 (COVIDâ€�19) â€� Situation Repor â€� 90 (April 19, 2020)</span>. <a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports</a>. Accessed April 19, 2020.</span></li> <li tag="ref"><a name="jmv25961-bib-0002" /><span class="label" tagx="label" title="label">2</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="collab'">collab: World Health Organization</span> . <span class="mixed-article-title" title="mixed-article-title">Clinical management of severe acute respiratory infection (SARI) when COVIDâ€�19 disease is suspected. Interim guidance 13 March 2020</span>. <a href="https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected">https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected</a>. Accessed April 18, 2020.</span></li> <li tag="ref"><a name="jmv25961-bib-0003" /><span class="label" tagx="label" title="label">3</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Casadevall</span><span class="given-names" tagx="given-names" title="given-names">Arturo</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Pirofski</span><span class="given-names" tagx="given-names" title="given-names">Liiseâ€�anne</span></span>. <span class="mixed-article-title" title="mixed-article-title">The convalescent sera option for containing COVIDâ€�19</span>. <span class="source" tagx="source" title="source">J Clin Invest</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">130</span>(<span class="issue" tagx="issue" title="issue">4</span>):<span class="fpage" tagx="fpage" title="fpage">1545</span>â€�<span class="lpage" tagx="lpage" title="lpage">1548</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32167489">32167489</a></span></span></li> <li tag="ref"><a name="jmv25961-bib-0004" /><span class="label" tagx="label" title="label">4</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="collab'">collab: Food and Drug Administration</span> . <span class="mixed-article-title" title="mixed-article-title">Recommendations for Investigational COVIDâ€�19 Convalescent Plasma, Content current as of: 04/13/2020</span>. <a href="https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma">https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma</a>. Accessed April 18, 2020.</span></li> <li tag="ref"><a name="jmv25961-bib-0005" /><span class="label" tagx="label" title="label">5</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Moher</span><span class="given-names" tagx="given-names" title="given-names">David</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Shamseer</span><span class="given-names" tagx="given-names" title="given-names">Larissa</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Clarke</span><span class="given-names" tagx="given-names" title="given-names">Mike</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Preferred reporting items for systematic review and metaâ€�analysis protocols (PRISMAâ€�P) 2015 statement</span>. <span class="source" tagx="source" title="source">Syst Rev</span>. <span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">4</span>:<span class="fpage" tagx="fpage" title="fpage">1</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25554246">25554246</a></span></span></li> <li tag="ref"><a name="jmv25961-bib-0006" /><span class="label" tagx="label" title="label">6</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Duan</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Effectiveness of convalescent plasma therapy in severe COVIDâ€�19 patients</span>. <span class="source" tagx="source" title="source">Proc Natl Acad Sci USA</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">117</span>(<span class="issue" tagx="issue" title="issue">17</span>):<span class="fpage" tagx="fpage" title="fpage">9490</span>â€�<span class="lpage" tagx="lpage" title="lpage">9496</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32253318">32253318</a></span></span></li> <li tag="ref"><a name="jmv25961-bib-0007" /><span class="label" tagx="label" title="label">7</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Shen</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">Z</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zhao</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Treatment of 5 critically Ill patients with COVIDâ€�19 with convalescent plasma</span>. <span class="source" tagx="source" title="source">JAMA</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">323</span>(<span class="issue" tagx="issue" title="issue">16</span>):<span class="fpage" tagx="fpage" title="fpage">1582</span>â€"<span class="lpage" tagx="lpage" title="lpage">1589</span>. <span class="pub-id"><a href="https://dx.doi.org/10.1001/jama.2020.4783">10.1001/jama.2020.4783</a></span></span></li> <li tag="ref"><a name="jmv25961-bib-0008" /><span class="label" tagx="label" title="label">8</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Tan</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Treatment with convalescent plasma for critically ill patients with SARSâ€�CoVâ€�2 infection</span>. <span class="source" tagx="source" title="source">Chest</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">S0012â€�3692</span>(<span class="issue" tagx="issue" title="issue">20</span>):<span class="fpage" tagx="fpage" title="fpage">30571</span>â€�<span class="lpage" tagx="lpage" title="lpage">30577</span>.</span></li> <li tag="ref"><a name="jmv25961-bib-0009" /><span class="label" tagx="label" title="label">9</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ahn</span><span class="given-names" tagx="given-names" title="given-names">JY</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Sohn</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">SH</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Use of convalescent plasma therapy in two covidâ€�19 patients with acute respiratory distress syndrome in Korea</span>. <span class="source" tagx="source" title="source">J Korean Med Sci</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">35</span>(<span class="issue" tagx="issue" title="issue">14</span>):<span class="elocation-id" tagx="elocation-id" title="elocation-id">e149</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32281317">32281317</a></span></span></li> <li tag="ref"><a name="jmv25961-bib-0010" /><span class="label" tagx="label" title="label">10</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ye</span><span class="given-names" tagx="given-names" title="given-names">Mingxiang</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Fu</span><span class="given-names" tagx="given-names" title="given-names">Dian</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ren</span><span class="given-names" tagx="given-names" title="given-names">Yi</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Treatment with convalescent plasma for COVIDâ€�19 patients in Wuhan, China</span>. <span class="source" tagx="source" title="source">J Med Virol</span>. <span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1002/jmv.25882">10.1002/jmv.25882</a></span></span></li> <li tag="ref"><a name="jmv25961-bib-0011" /><span class="label" tagx="label" title="label">11</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Luke</span><span class="given-names" tagx="given-names" title="given-names">TC</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kilbane</span><span class="given-names" tagx="given-names" title="given-names">EM</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Jackson</span><span class="given-names" tagx="given-names" title="given-names">JL</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Metaâ€�analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?</span><span class="source" tagx="source" title="source">Ann Intern Med</span>. <span class="year" tagx="year" title="year">2006</span>;<span class="volume" tagx="volume" title="volume">145</span>(<span class="issue" tagx="issue" title="issue">8</span>):<span class="fpage" tagx="fpage" title="fpage">599</span>â€�<span class="lpage" tagx="lpage" title="lpage">609</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16940336">16940336</a></span></span></li> <li tag="ref"><a name="jmv25961-bib-0012" /><span class="label" tagx="label" title="label">12</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Soo</span><span class="given-names" tagx="given-names" title="given-names">YO</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Cheng</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wong</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Retrospective comparison of convalescent plasma with continuing highâ€�dose methylprednisolone treatment in SARS patients</span>. <span class="source" tagx="source" title="source">Clin Microbiol Infect</span>. <span class="year" tagx="year" title="year">2004</span>;<span class="volume" tagx="volume" title="volume">10</span>(<span class="issue" tagx="issue" title="issue">7</span>):<span class="fpage" tagx="fpage" title="fpage">676</span>â€�<span class="lpage" tagx="lpage" title="lpage">678</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15214887">15214887</a></span></span></li> <li tag="ref"><a name="jmv25961-bib-0013" /><span class="label" tagx="label" title="label">13</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Hung</span><span class="given-names" tagx="given-names" title="given-names">IF</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">To</span><span class="given-names" tagx="given-names" title="given-names">KK</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">CK</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection</span>. <span class="source" tagx="source" title="source">Clin Infect Dis</span>. <span class="year" tagx="year" title="year">2011</span>;<span class="volume" tagx="volume" title="volume">52</span>(<span class="issue" tagx="issue" title="issue">4</span>):<span class="fpage" tagx="fpage" title="fpage">447</span>â€�<span class="lpage" tagx="lpage" title="lpage">456</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21248066">21248066</a></span></span></li> <li tag="ref"><a name="jmv25961-bib-0014" /><span class="label" tagx="label" title="label">14</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zhou</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zhong</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Guan</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>. <span class="mixed-article-title" title="mixed-article-title">Treatment with convalescent plasma for influenza A (H5N1) infection</span>. <span class="source" tagx="source" title="source">N Engl J Med</span>. <span class="year" tagx="year" title="year">2007</span>;<span class="volume" tagx="volume" title="volume">357</span>(<span class="issue" tagx="issue" title="issue">14</span>):<span class="fpage" tagx="fpage" title="fpage">1450</span>â€�<span class="lpage" tagx="lpage" title="lpage">1451</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17914053">17914053</a></span></span></li> <li tag="ref"><a name="jmv25961-bib-0015" /><span class="label" tagx="label" title="label">15</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="collab'">collab: World Health Organization</span> . <span class="mixed-article-title" title="mixed-article-title">Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks</span>. <a href="https://www.who.int/csr/resources/publications/ebola/convalescent-treatment/en/">https://www.who.int/csr/resources/publications/ebola/convalescent-treatment/en/</a> Updated 2014. Accessed April 18, 2020.</span></li> <li tag="ref"><a name="jmv25961-bib-0016" /><span class="label" tagx="label" title="label">16</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Cheng</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wong</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Soo</span><span class="given-names" tagx="given-names" title="given-names">YO</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Use of convalescent plasma therapy in SARS patients in Hong Kong</span>. <span class="source" tagx="source" title="source">Eur J Clin Microbiol Infect Dis</span>. <span class="year" tagx="year" title="year">2005</span>;<span class="volume" tagx="volume" title="volume">24</span>(<span class="issue" tagx="issue" title="issue">1</span>):<span class="fpage" tagx="fpage" title="fpage">44</span>â€�<span class="lpage" tagx="lpage" title="lpage">46</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15616839">15616839</a></span></span></li> <li tag="ref"><a name="jmv25961-bib-0017" /><span class="label" tagx="label" title="label">17</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Syal</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>. <span class="mixed-article-title" title="mixed-article-title">COVIDâ€�19: herd immunity and convalescent plasma transfer therapy</span>. <span class="source" tagx="source" title="source">J Med Virol</span>. <span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1002/jmv.25870">10.1002/jmv.25870</a></span></span></li> <li tag="ref"><a name="jmv25961-bib-0018" /><span class="label" tagx="label" title="label">18</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>. <span class="mixed-article-title" title="mixed-article-title">Potential interventions for novel coronavirus in China: a systematic review</span>. <span class="source" tagx="source" title="source">J Med Virol</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">92</span>(<span class="issue" tagx="issue" title="issue">5</span>):<span class="fpage" tagx="fpage" title="fpage">479</span>â€�<span class="lpage" tagx="lpage" title="lpage">490</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32052466">32052466</a></span></span></li> </ul> </div> </div>  </body></html>